• Molecular NameRimonabant
  • Synonymrimonabant; SR 141716; SR 141716A; SR141716; SR141716A
  • Weight463.796
  • Drugbank_IDDB06155
  • ACS_NO158681-13-1
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)5.32
  • pkaN/A
  • LogD (pH=7, predicted)5.32
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-6.91
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors1
  • No.of HBond Acceptors5
  • No.of Rotatable Bonds4
  • TPSA49.64
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn anorectic anti-obesity drug. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite.
  • Absorption_valueN/A
  • Absorption (description)Undetermined
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding100.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic, CYP3A4 involved
  • Half lifeVariable: 6 to 9 days with normal BMI; 16 days if BMI >30
  • ExcretionFecal (86%) and renal (3%)
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityAlmost twice as many people discontinued rimonabant compared with placebo because of adverse events (13.8% vs. 7.2%). These consistently involved psychiatric disorders (8.5% vs. 3.2%), including depression and anxiety. Other common side effects included insomnia, nausea, vomiting, diarrhoea and fatigue.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A